In spite of the success of the mumps vaccination, recent mumps outbreaks have been reported even among individuals with a history of mumps vaccination. For a better understanding of why the vaccination failed in cases of vaccinees who fell ill during recent mumps outbreaks, the immunological events during infection and/or vaccination should be better defined. In the work presented here we sought to identify new neutralization sites on the mumps virus surface glycoproteins. By using anti-mumps mAbs, three amino acid positions at residues 221, 323 and 373 in the F protein of mumps virus were shown to be located in at least two conformational neutralization epitopes. mAbs that specifically target these sites effectively neutralized mumps virus in vitro. The newly acquired glycosylation site at position 373 or loss of the existing one at position 323 was identified as the mechanism behind the escape from the specific mAbs. Based on the findings of this study, we suggest that the influence of the antigenic structure of the F protein should not be ignored in a thorough investigation of the underlying mechanism of the mumps vaccine failure or when making a strategy for development of a new vaccine.
INTRODUCTION
Mumps virus is a member of the family Paramyxoviridae with a 15 384 nt genome that contains non-segmented, single-stranded, negative-sense RNA. Mumps is a selflimiting, highly contagious disease with typical symptoms such as swollen parotid glands, fever, headache and pain. In some cases, severe complications may occur, like orchitis or pancreatitis, or the infection may affect the central nervous system causing meningitis and, in rare cases, encephalitis. Mumps virus vaccines based on attenuated mumps virus have effectively reduced the incidence of mumps worldwide. The major target of the anti-mumps antibodies is haemagglutinin-neuraminidase (HN) (Rubin et al., 2012) , which is anchored in the viral envelope together with the fusion (F) protein, a second viral glycoprotein. The HN protein has triple role in viral infection: initial attachment to a sialic acid-containing receptor, cleavage of the receptor and activating the F protein. The F protein is synthesized as a biologically inactive F 0 precursor from which a pre-fusion metastable form of disulfide-linked F 2 +F 1 is formed by the proteolytic action of the cellular endoprotease furin, a ubiquitous subtilisin-like cellular endoprotease that recognizes an R-X-K/R-R motif (Chang & Dutch, 2012) . Binding of the HN protein to the receptor initiates the F protein to undergo conformational changes which ultimately lead to the fusion of the viral and cellular membranes Bose et al., 2013) and the entrance of viral ribonucleoprotein complex into the cell. Current knowledge about the neutralization target sites for the anti-mumps antibodies is limited. Three epitopes on the HN were described previously spanning aa 265-288, 329-340 and 350-360 (Kövamees et al., 1990; Ö rvell et al., 1997; Cusi et al., 2001) . There are indications that there are other neutralization sites (Šantak et al., 2013) .
The role of the F protein induced antibodies has been confirmed for many paramyxoviruses: parainfluenza type 5 (Paterson et al., 1987) , canine distemper virus (Norrby et al., 1986) , respiratory syncytial virus (Malley et al., 1998) , Newcastle disease virus (Toyoda et al., 1988) and human metapneumovirus (Cseke et al., 2007) . Merz et al. (1980) showed that effective immunological prevention of the spread of paramyxovirus infection requires the presence of antibodies that neutralize the F glycoprotein, which is explained by the dichotomous action of anti-F antibodies. These antibodies can block the spread of virus released as progeny virus, or the spread of virus that infects adjacent cells as a result of the cell-fusing activity of the F glycoprotein. Anti-HN antibodies block only spread of viruses released as progeny virus. This requirement for IP: 54.70.40.11 On: Thu, 27 Dec 2018 20:27:29 anti-F antibodies has obvious implications for the design of effective paramyxovirus vaccines and provides an explanation for previous failures of formalin-inactivated paramyxovirus vaccines, as well as providing additional insight into the possible immunopathological mechanisms involved in the atypical and severe infections that have occurred in individuals who received inactivated vaccines and were subsequently infected by the virus.
In spite of the importance of the F protein for the immune response to paramyxoviruses, data on antigenic structure of the F protein of mumps virus is both limited and controversial. Studies by Ö rvell (1984) and Wolinsky et al. (1985) showed inability of anti-F antibodies to neutralize virus and Rubin et al. (2012) showed that, while the HN is a major target of neutralizing antibodies, the F protein did not play a significant role in the neutralizing antibody response in their study. In contrast, efficacy of the anti-F antibodies was shown in the study by Houard et al. (1995) where F protein expressed in hamsters via vaccinia vector induced effective neutralizing antibodies. Also, antigenic analysis of the F protein by Tecle et al. (2000) showed that the structure and antigenicity of this protein is well conserved both intra-and inter-genotypically over long periods of time, with only low levels of differences between A and B genotypes and C and D genotypes. In spite of the success of the mumps vaccination, recent mumps outbreaks have been reported even among individuals with a history of mumps vaccination (Dayan & Rubin, 2008) . Analysis by Homan & Bremel (2014) showed that there are differences in predicted B-cell linear epitope and potential T-cell epitopes between the JL5 vaccine strain and other virus strains, helping to frame a hypothesis for the circumstances that can lead to a resurgence of mumps cases in previously vaccinated individuals. Therefore, to understand better the underlying mechanism of vaccine failure in cases of vaccinees who fell ill during recent mumps outbreaks, there is a necessity to better define the immunological events in the infected human body and/or during vaccination. In the work presented here, we sought to identify new neutralization sites on the mumps virus surface glycoproteins HN and F.
RESULTS AND DISCUSSION

Selection of mAbs specific for the mumps virus glycoproteins HN and F
To select anti-HN and anti-F antibodies, screening of 64 mouse mAbs was performed by a plaque reduction neutralization test (PRNT) with the Du/CRO05 mumps virus strain. The lowest neutralization titre in the PRNT was 3.61 log ND 50 , so the mAbs with titres above 3.9 log ND 50 (twofold higher titre) were selected as the neutralizing mAbs. According to this criteria, 19 of 64 mAbs were chosen for the selection of escape mutants from the Du/ CRO05 virus (Table 1) . Other mAbs were excluded from further analysis due to titres lower than the set values. To further distinguish conformational nonlinear epitopes from linear epitopes, a dot blot with non-denatured and denatured viruses was hybridized with the 19 selected mAbs. Two out of 19 mAbs were shown to be specific for linear epitopes and 17 were specific for conformational epitopes (Table 1) , showing that the majority of epitopes at the surface glycoproteins are conformational. Therefore, only conformational epitopes were subject to further study.
Selection and analysis of mumps virus escape mutants
To select viral escape mutants specific for each of the chosen mAbs, the original Du/CRO05 virus was subjected to three rounds of mAb treatment and finally plaque purification. Twelve plaques were picked for each mAb. To confirm which of the picked plaques contained escape mutants, each plaque was grown in Vero cells and used in a haemagglutination inhibition test. Only those plaques that absolutely avoided inhibition of haemagglutination were considered to be escape mutants. Others were considered as either non-escape mutants or mixed plaques. From 17 selected mAbs, 11 mAbs yielded escape mutants which did not show any sign of inhibition of haemagglutination: m104, m112, m114, m125, m126, m156, m169, m175, m222, m1256 and m1264 (Table 1) . To reveal which amino acid residue was responsible for the escape from the mAb, for each plaque-purified escape mutant, the F and HN gene sequences were determined. No mutations were found in the HN gene. A very plausible explanation for this is the genetic difference in the HN sequence between the virus used to obtain mAbs (i.e. SBL-1 strain) and the virus used for selection of escape mutants (i.e. Du/CRO05). The differences in the regions 265-288 and 350-360 match exactly to the residues previously identified by Ö rvell et al. (1997) to be the neutralization epitope escape mutants (aa 265, 266, 287, 354, 356, 368 and 372) . Nevertheless, an additional neutralization site could have been identified but it seems that the two epitopes are dominant in the relatively small number of mAbs used here. Therefore, to identify less pronounced neutralization sites, a highthroughput method should be used in the future. Also, the overall difference in the two HN and F proteins is 6.0 and 3.5 % (shown respectively in Figs S1 and S2, available in the online Supplementary Material) indicating that possible additional neutralization sites may be in regions containing differences causing weaker binding of mAbs in the neutralization test and inhibition of haemagglutination assay, and thus these mAbs would be in the grey zone of the test and would be excluded from the analysis.
The genetic analysis of the F gene of the escape mutants revealed three amino acid positions that distinguish them from the original Du/CRO05 virus: 221 (IleAThr), 323 (AsnAHis) and 373 (AspAAsn) ( Table 1) . All three amino acid residues were located in the F 1 part of the F protein.
To confirm the relevance of the identified neutralization sites, representative escape mutant viruses of each of the identified three amino acid residues were produced: m156_3 for position 221 (IleAThr), m104_4 for position 323 (AsnAHis) and m114_4 for position 373 (AspAAsn). The replication kinetics of selected escape mutants were measured in Vero cells (Fig. 1a ). As shown in Fig. 1(a) , the replication kinetics were similar for all three escape mutants and they were also similar to the replication kinetic of the original virus (Du/CRO05), so the identified mutations do not significantly change the viral fitness for growth. Next, the escape mutant viruses and the original virus were assayed by the PRNT (Fig. 1b ). Each mAb significantly neutralized all viruses, but the associated escape mutant virus originated from the selection process that involved that particular mAb. There was .1 log ND 50 (for m156) or .2 log ND 50 (for m104 and 114) difference in the neutralization titre of mAbs between the associated escape mutant and other two escape mutants and the original virus. Thus, the mAbs recognizing these three sites of the F protein strongly reduce infection capacity of the virus in vitro. 
Analysis of the neutralization sites in the F protein of mumps virus
The analysis of the sequence electropherogram of the original virus Du/CRO05 showed that nucleotide position 5662 (aa 373) was a mix of A and G, with A prevailing over G, while the other two nucleotide positions, 5207 (aa 221) and 5512 (aa 323) did not show any heterogeneity (data not shown). Hence, the escape mutant with the mutated aa 373 originated from the variant pre-existing in the original virus, while the escape mutants with mutated positions 221 and 323 probably originated during the selection process or from a variant which pre-existed in the original virus but in a very low amount.
The alignment of the F protein of the original virus, the escape mutant viruses identified in this study and several more mumps viruses showed that the mutated aa 221, 323 and 373 are well conserved among different mumps virus strains belonging to different genotypes, and collected from the 1950s until 2011 ( Fig. 2a-c) , which agrees with the finding of Tecle et al. (2000) that the F protein is structurally and antigenically well conserved both intraand inter-genotypically over long periods of time, with only low level of differences between A and B genotypes and C and D genotypes.
Two out of three different amino acid residues (those at positions 221 and 373), which were shown to cause viral escape from the mAbs, were identified by the same mAb (in cases of mAbs m156, m175, m222 and m1256, Table 1) indicating that they are part of the common conformational epitope. However, it cannot be ruled out that the amino acid residue at position 373 is also part of another epitope which does not include the residue at position 221 because escape mutants carrying a mutated 373 position were obtained by 10 mAbs, out of which six mAbs generated viruses (total of 63 escape mutants) mutated only in that position, while four mAbs generated viruses (total of 45 escape mutants) were mutated either at position 221 or 373 (Table 1) .
Prediction of the structure of the monomeric form of the F protein generated by structural modelling shows that residues 221 and 373 are distant, and as such cannot be part of the same epitope (Fig. 3, upper panel) . However, it was shown that all paramyxoviruses present a homotrimeric fusion protein on their surface. The modelling of the structure of the mumps virus F protein as a homotrimer using a homology model based on the structure of the parainfluenza type 5 F protein in its metastable pre-fusion conformation (Yin et al., 2006) revealed that residues 221 and 373 can lie in proximity in the homotrimeric prefusion form. This will happen only in the trimeric form where three molecules of the F protein join in such a way that the residue 221 of one F molecule comes into the vicinity of the residue 373 of another F molecule, and thus they can form a single epitope (Fig. 3, lower panels) .
Glycosylation as the mechanism behind the escape from the anti-F mAbs For two escape mutants, m104_4 and m114_4, the origin of the escape involves amino acid Asn: m104_4 lost Asn at position 323 and m114_4 gained Asn at position 373. Asn is the amino acid which is prone to N-linked glycosylation (Johansen et al., 1961) . To investigate if the N-glycosylation plays a role in the binding of the mAbs to specific epitopes, the binding of mAbs to escape mutant viruses treated with PNGase F (N-glycosidase F) was analysed ( Fig.  4) . Although the Asn at position 323 is not part of the Nglycosylation consensus sequence motif Asn-X-Ser/Thr-X (where X is any amino acid except Pro), it is possible that this amino acid is still glycosylated, only with less likelihood. As shown in Fig. 4(a) , the removal of the Nlinked glycan in the original Du/CRO05 virus reduced binding of m104 mAb, indicating that glycan at the Asn323 is essential for binding of the m104 mAb to the virus, and the loss of glycan abolishes specificity of the mAb. The Asn at position 373 in escape mutant m114_4 creates a new consensus sequence motif Asn-Gly-Thr-Ile, which does not exist in the original virus (Asp-Gly-Thr-Ile). The treatment with PNGase F removes glycan from the Asn373, which is also hydrolysed to Asp, and the binding affinity of the m114 mAb is restored to the level observed with original virus (Fig. 4b) . Thus, glycan at the Asn373 hinders binding of the m114 mAb to its target site. The escape mutant m156_3 has a modification at position 221 where Ile is replaced with Thr. In this case, the N-glycosylation does not play a role, and this is shown in Fig. 4(c) . However, the O-linked glycosylation often involves Thr, so it cannot be ruled out that glycosylation here also obstructs the binding of mAb. Also, the replacement of the non-polar, hydrophobic Ile with the polar Thr can be the cause of the Fig. 2 . Alignment of the escape mutant viruses (m104_4, m114_4 and m156_3) and different mumps virus strains at aa 221 (a), 323 (b) and 373 (c) and several adjacent amino acids. Amino acids responsible for the escape from the mAb are indicated by an arrow. Numerals and asterisks denote amino acid position in the F protein.
structure modification which may change the affinity of the mAb to the specific target site.
To conclude, in the study presented here, three amino acid positions in the F protein of the mumps virus were shown to facilitate the escape from mAb, indicating that they are located in neutralization epitopes. Additionally, two amino acids were found to be located in a single epitope. mAbs which specifically target these sites effectively neutralize mumps virus in vitro. The relevance of these neutralization sites and associated mAbs in vivo remains to be investigated, as well as the resemblance of the mouse mAbs used here and the humoral response in humans. The newly acquired glycosylation site or loss of the existing one are identified as the mechanism behind the escape from the specific mAbs for at least two of the amino acid residues identified. Based on the above findings, we suggest that for an investigation of the cause of the mumps vaccine failure or when making a strategy for development of the new vaccine, the influence of the antigenic structure of the F protein should not be ignored.
METHODS
Cells and viruses. Vero cells (African green monkey kidney cells)
were purchased from ATCC and maintained in minimum essential medium with Hank's salts (MEM-H) supplemented with 10 % FCS and 50 ml neomycin ml 21 . The BALB/c myeloma cell line P3663Ag8 (obtained from the Department of Tumour Biology, Karolinska Institute, Stockholm) was maintained in Dulbecco's modified Eagle's medium supplemented with 8 % heat-inactivated FCS, penicillin and streptomycin (Togashi et al., 1981) . The F0 cells, derived from a BALB/c myeloma cell line, was kindly put at our disposal by Fazekas de St Groth and Doris Scheidegger, Basel Institute for Immunology, Switzerland. The cells were maintained in RPMI 1640 medium, pH 7.2, supplemented with 10 % heat-inactivated FCS, 2 mM sodium pyruvate, 0.05 % sodium glutamine, penicillin and streptomycin (de St. Groth & Scheidegger, 1980) . Virus was quantified by a plaque test as described by Forcic et al. (2010) .
Mumps virus strains
mAbs. The procedure for production of mAbs has been described previously (Ö rvell & Grandien, 1982) , with the exception that the BALB/c myeloma cell line P3663Ag8 cells were used in fusion experiments with spleen cells from BALB/c mice immunized with enriched envelope antigen preparations derived from purified mumps virions, as described previously (Ö rvell, 1978; Ö rvell & Grandien, 1982) . In brief, the SBL-1 virus strain was grown in the allantoic sac of 7-9-day-old chicken embryos. The allantoic fluid was harvested after incubation for 5 days at 37 uC. After clarification by low-speed centrifugation, the virus was concentrated by high speed centrifugation at 140 000 g for 90 min. The virus pellet was washed five times with PBS after which further purification of the virus was obtained by ultracentrifugation in discontinuous sucrose gradients to the interphase between the 30 and 60 % (w/w) sucrose layers. An enrichment of envelope proteins was carried out by treatment of the purified virions (2 mg ml 21 in 0.01 M phosphate buffer, pH 7.2) with 1 % of the non-ionic detergent octyl glucoside for 15 min at room temperature, followed by centrifugation at 30 000 r.p.m. for 30 min in a SW50 rotor (Ö rvell & Grandien, 1982) . The supernatant, which predominantly contained envelope proteins of the virus, was used for immunization.
Two mAbs (mouse 1256 and 1264) were produced in fusion experiments with F0 cells. The mAbs had not been characterized in previous work (Ö rvell, 1984) .
Haemagglutination and inhibition of haemagglutination. A haemagglutination assay was performed according to Mahy & Kangro (1995) with the exception that 0.5 % guinea pig erythrocyte suspension was used. Serial twofold dilutions of virus were used in the test and the last dilution showing complete agglutination was defined as containing one haemagglutinating unit (HAU). Inhibition of haemagglutination was performed with mAbs heat inactivated at 56 uC for 30 min, treated with 12.5 % PBS-washed kaolin suspension (pH 7.5) for 30 min at room temperature and finally treated with 0.5 % guinea pig erythrocytes for 1 h at 37 uC. Each mAb was prepared in serial dilutions (1 : 1 with PBS) starting from dilution 1 : 20 and 4 HAU of virus was added. After incubation at 35 uC for 1 h, the same volume of 0.5 % guinea pig erythrocytes was added and the titre was determined after 1 h at room temperature.
PRNT. A PRNT was performed as described by Cohen et al. (2007) , with some modifications. mAbs were prepared in six fourfold dilutions starting from at least one dilution completely neutralizing added virus, and ending with at least one dilution having no neutralizing capacity. The starting dilution for mAbs that were shown not to be capable of neutralizing the virus was 1/8. The virus used for neutralization was Du/CRO05. The concentration of the virus was adjusted to 250±50 p.f.u. ml 21 with MEM-H with 2 % FCS. The test was performed in 24-well plates in which Vero cells were seeded at concentration 1610 5 cells per well 48 h prior to the addition of a mixture of serum and virus. Each dilution of the mAbs was mixed with an equal volume of virus and incubated at 35 uC for 1 h. Then the medium was removed from the plate and 0.2 ml mixture was transferred into four wells in the plate. Each assay run included controls: virus as a positive control, and medium used for diluting the sera and viruses as a negative control. The plates were incubated at 35 uC for 1 h, the mixture of serum and virus was removed and the cells were overlaid with 0.6 ml semi-solid medium consisting of 1, v/v, 26 MEM-H with 10 % FCS without phenol red and 1, v/v, 1.5 % Noble agar (Sigma). Plates were incubated at 35 uC in a humidified atmosphere of 5 % CO 2 . After 6 days, the monolayers were stained with 1 ml of 0.05 % neutral red (Sigma) and plaques were counted. Fifty per cent end-point titres were calculated using the Kärber formula: log 10 ND 50 52max 2 D(gp 20.5), where max is the log 10 of the highest dilution of serum in the test, D is log 10 of the dilution factor (for fourfold dilutions this is 20.6) and gp is total number of plaques divided by the number of plaques in the positive-control sample.
Selection of escape mutants. For the selection of escape mutants, three passages of virus infection upon treatment with mAbs were carried out. In the first passage, 1610 5 p.f.u. per 100 ml virus was treated with 50 ml mAb and incubated at 35 uC for 1 h. The virus and mAb mixture was then added to confluent Vero cells and further incubated at 35 uC for 1 h. The cells were washed three times with PBS and MEM-(H) with the addition of 2 % FCS, and 50 ml of the same mAb was added. The virus was grown for 2 days, and then the procedure was repeated two more times with 100 ml of the previous passage. After the third passage, the virus in the Vero cell supernatant was diluted in six tenfold dilutions and a plaque test was performed on Vero cells as described in Forcic et al. (2010) . After 6 days, 12 plaques were picked for each virus and mAb combination and transferred to new Vero cell culture in MEM-(H) with 2 % FCS. After 24 h, the medium was replaced with medium without serum and virus was further grown until cytopathic effect was observed. The viruses were then ultracentrifuged at 142 000 g for 2 h and used in haemagglutination inhibition tests to select escape mutant viruses that were no longer inhibited by the mAb. Only those viruses that were absolutely non-reactive with mAb were further analysed.
Analysis of the HN and F genes. Viral RNA was isolated from Vero cell supernatants by the method of Chomczynski & Sacchi (1987) . cDNA was prepared with murine leukemia virus reverse transcriptase and random hexamers. The HN gene was amplified in three parts: the HN part I (6422-7203 nt), amplified with primers HN1 59-GTTTCG-ATAACCCACTCTAGA-39 and LZ4 59-CACATTATGTGTATAGCA-ACC-39; the HN part II (7082-7793 nt), amplified with primers LZ9 59-TTCTCTATCGGCCATCCACT-39 and LZ6 59-GCTCGCAATTT-GTAACTAGG-39; and the HN part III (7763-8474 nt), amplified with primers LZ10 59-CTCAGGACCACAACAAGA-39 and LZ8 59-GTACTTCAGGTAAGAGTATC-39. The F gene was also amplified in three parts: the F part I (4424-5120 nt), ampified with primers F1 59-AGAATCAACAATCAGTCCG-39 and F2 59-AGCTGGTTATCAAGG-ATCT-39; the F part II (5041-5776 nt), amplified with primers F3 59-CAAGCAATACAAGACCACA-39 and F4 59-GACATGCGGTTAG-ATCAAT-39; and the F part III (5734-6249 nt), amplified with primers F5 59-CCTGACCATCATGCAGTCA-39 and F6 59-TCACG-AGACGTTACGACC-39.
All PCRs had the same conditions: 94 uC for 4 min, then 40 cycles 94 uC for 30 s, 50 uC for 20 s and 72 uC for 2 min, followed by final extension at 72 uC for 10 min. The reaction mixture contained 16 PCR buffer (GE Healthcare), 10 mM dNTPs, 0.25 mM MgCl 2 , 0.4 mM each primer and 5 U Taq polymerase (GE Healthcare). Sequencing reactions were set up with purified DNA, specific primer used in PCR and BigDye Terminator v3.1 Cycle Sequencing kit (Life Technologies), according to the protocol recommended by the manufacturer. Sequencing and analysis of sequences were performed on a 3130 Genetic Analyzer (Life Technologies).
Sequences obtained from the GenBank included in alignments are (accession numbers are given in parentheses): Du/CRO05 (EU370207), MuVi/Split.CRO/05.11 (JN635498), 9218/Zg98 (EU370206), JL5 (AF338106), L-Zagreb (AY685920), UrabeAM9 (AF314559), ZgA/ Cro69 (AY376470), ZgB/Cro69 (AY376471), SA702/Ja99 (AB085216), SA369/Ja00 (AB085217), SA963/Ja00 (AB085220), Biken (AF314561), Enders (GU980052), Lit-1013 (AY502056), MuVi/Utrecht.NLD/ 40.10 (KJ125068), S-12 (DQ525022), Glouc1/UK96 (AF280799), SP (EU884413), MuVi/Novosibirsk.RUS/10.03 (AY681495), Dg1062/ Korea/98 (AY309060), SBL-1 (AF143395), V31 (AF1433390), 88-1961 (AF467767) and Zg/CRO06 (KM360091).
All alignments were performed by using Clone Manager Suite software (Scientific & Educational Software).
Bradford protein assay. Samples were diluted 1 : 500 in Bradford solution [100 mg l 21 Coomassie Brilliant Blue G-250, 5 % (v/v) methanol, 10 % (v/v) ortho-phosphoric acid] and incubated for 5 min. The sample absorbance was measured at 595 nm and BSA was used as a standard.
Deglycosylation of viral proteins and dot-blot analysis of deglycosylated proteins. Virus was obtained by infection of Vero cells which were grown in medium without serum until cytopathic effect was observed. Then 35 ml of the virus was ultracentrifuged at 142 000 g for 2 h and resuspended in PBS. For each peptide-Nglycosidase (PNGase) treatment, a volume of virus containing 30 mg protein was used. PNGase F (Roche) was used at a concentration of 0.2 U per sample -1 in buffer containing 0.5 % Igepal (Sigma) and 10 mM EDTA, pH 7.2. Deglycosylation was performed at 37 uC for 18 h.
For dot-blot analysis, a PVDF membrane was soaked in buffer containing 190 mM glycine, 25 mM Tris/HCl and 20 % methanol and spotted with 30 mg of either denatured or non-denatured viral samples. Samples were denatured by addition of 2.5 % SDS and 250 mM DTT, and heating at 95 uC for 5 min. The membrane was blocked with 5 % skimmed milk, 5 mM Tris/HCl, pH 7.5, and 150 mM NaCl for 30 min with agitation. Each mAb was used diluted 1 : 250, and secondary rabbit anti-mouse-AP (Santa Cruz) was diluted 1 : 5000; both mAbs were diluted in blocking solution. The signal was obtained by the addition of ECF Substrate (GE Healthcare) and the intensity was measured by densitometry analysis provided by Kodak software at the Kodak Image Station 440CF (Kodak).
Protein structure prediction. Protein structure was predicted using a homology SWISS-model platform (Arnold et al., 2006; Bordoli et al., 2009; Biasini et al., 2014 , http://swissmodel.expasy.org).
Statistical analyses. A two-tailed unpaired t-test was used to calculate statistical significance.
